Oculis raises $15.7M in an extension of its B series founding round announced in 2018.
Oculis SA, a Reykjavik, Iceland and Lausanne, Switzerland-based clinical-stage biopharmaceutical company developing next-generation topical ophthalmic treatments, announced that it has successfully raised a further CHF15.5M ($15.7M) in an extension of its Series B financing round, announced in January 2018.
The announcement brings a total funding amount to CHF35.5M ($36M).
In conjunction with this fundraising, Henry Skinner, Ph.D., Senior Vice President at Tekla Capital Management, is joining the Oculis Board of Directors as a Non-Executive Director. Dr. Skinner was formerly Managing Director at Novartis Venture Fund and Executive Director, Head Strategic Alliances at Novartis Institute for Biomedical Research. Prior to this, Dr. Skinner was CEO at SelectX Pharmaceuticals, President and CEO at NeoGenesis Pharmaceuticals and also spent four years at Pfizer in its Technology Acquisitions and Operations group.
At the same time, Stefan J. Sveinsson has stepped down from the Board of Directors.
The funds will be used to expand the company’s portfolio through strategic in-licensing and to advance the development of its emerging pipeline of novel topical (eye drop) treatments for major ophthalmic diseases.
Oculis SA, founded in 2003 by Einar Stefansson and Thorsteinn Loftsson, is a clinical-stage biopharmaceutical company whose mission is to develop novel topical treatments (eye drops) for ophthalmic diseases for both back- and front-of-the-eye in order to improve the sight and lives of patients worldwide.
At the beginning of 2018, the company re-located its corporate headquarters to Lausanne, Switzerland, while its R&D is based in Reykjavik, Iceland.